Fig 1.
Representative computed tomography (CT) images used to calculate spleen volume.
Non-small cell lung cancer (*). Baseline axial CT scans and follow-up scans in a responder patient (A-D) and a non-responder (E-H).
Table 1.
Patient demographic and tumor characteristics.
Fig 2.
Splenic volume does not show significant changes in NSCLC patients with and without clinical benefit treated with pembrolizumab.
The boxplots show the median spleen volume of NSCLC treated with pembrolizumab at baseline, after 12 weeks of treatment and the change in splenic volume between patients with and without clinical benefit.
Fig 3.
Splenic volume does not show significant changes in responders and non-responders.
The boxplots show the median pre-treatment splenic volume, post-treatment splenic volume or change in splenic volume between responders and non-responders.
Fig 4.
Kaplan-Meier curves for time to disease progression.
The Kaplan-Meier curves show the median time to progression between patients with clinical benefit to treatment versus those without benefit to treatment stratified using the median pre-treatment splenic volume, post-treatment splenic volume and change in splenic volume.